Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase I/IIa Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease

Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase I/IIa open label clinical trial to assess safety and tolerability of ANPD001.